Our Goals

To align the incentives of all stakeholders involved in the patients’ healthcare journey related to sustainable strategies to improve medication adherence and persistence in patients with Type 2 diabetes.

Assess how improving medication adherence/ persistence improves critical clinical surrogates (HbA1c, renal function, lipids, blood pressure, weight).

Close the gap between clinical trial findings and real-world patient care.

Establish real world evidence related to drivers of medication adherence and related solutions to improve health and economic outcomes.

An Integrated Approach to Real World Evidence

About P-MAPP

Established under a Research Collaboration Agreement with the U.S. Food and Drug Administration (FDA), the P-MAPP links comprehensive longitudinal patient-centric data, acquired in the "voice of the patient" via customized surveys, with information contained in patient health records, pharmacy fill/refill information and medical claims to create a de-identified, aggregated database of real world medication adherence/persistence and clinical outcomes.

The P-MAPP is unique in its randomized design, implementation in multiple pharmacy settings and use of predictive analytics to define drivers of non-adherence behaviours.

P-MAPP’s distinctive platform combines digital technologies, predictive analytics, and provider engagement to create personalized intervention strategies to address, monitor, and modify patients’ behaviors related to medication non-adherence.
  • Focuses on patients’ insights and engagement in care.
  • Stratifies patients taking oral verses injectable agents for the treatment of Type 2 diabetes.
  • Randomizes patients into two groups receiving either Routine Care or Routine Care plus Motivational Interviewing sessions with the pharmacists to define personalized strategies to improve adherence.
  • Collects and analyzes multiple disparate data from real-world sources; uses AI to produce actionable data.
  • Provides an “early warning” system for potential adverse events and notifies all providers.
  • Easy onboarding of patients at multiple points of service.

The P-MAPP includes many "FIRSTS":​

  • First to align the incentives of all of the stakeholders to deploy sustainable strategies to address the $386B burden to the healthcare delivery system due to medication non-adherence.
  • First program to provide data that attributes pharmacists’ performance to clinical outcomes related to improvement in medication adherence; data that can be used in support of provider status for pharmacists.
  • First program to provide ongoing monitoring to prescribers related to interventions to improve adherence that can be used in reimbursement under the value-based payment and performance models.
  • First pharmacist-based program that combines digital technologies, predictive analytics and patient engagement to improve medication adherence.
  • First digital app for patients, provided by pharmacists, that monitors ongoing behavior attributed to nonadherence and provides personalized intervention strategies to improve outcomes.
“The patient is the most underused resource in healthcare.”
Warner Slack MD, Harvard Medical School
Electronic Medical Records Pioneer and Champion of “Patient Power”